Drug Approval | January 24, 2026
Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India
Company to launch product after the expiry of semaglutide patent in India
Company to launch product after the expiry of semaglutide patent in India
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
Subscribe To Our Newsletter & Stay Updated
